Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APC | P25054 | 3/20 | 0.58 |
| ▸ | BACE1 | P56817 | 3/20 | 0.53 |
| ▸ | QRFPR | Q96P65 | 2/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | CCKBR | P32239 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30570452 | 0.83 | OPRL1 (0.50) | BACE1QRFPROPRD1OPRM1OPRK1 | |
| SCHEMBL29939679 | 0.83 | APC (0.55) | APCBACE1QRFPRKEAP1OPRD1 | |
| SCHEMBL29512270 | 0.83 | APC (0.55) | APCBACE1QRFPRKEAP1OPRD1 | |
| SCHEMBL31256956 | 0.82 | OPRD1 (0.57) | APCBACE1OPRD1OPRM1OPRK1 | |
| SCHEMBL29670260 | 0.82 | TFPI (0.56) | APCBACE1QRFPR | |
| SCHEMBL30643193 | 0.81 | OPRM1 (0.58) | APCBACE1KEAP1PTPN1OPRD1 | |
| SCHEMBL30445627 | 0.81 | OPRM1 (0.54) | OPRD1OPRM1OPRK1 | |
| SCHEMBL31005067 | 0.81 | BACE1 (0.70) | BACE1 | |
| SCHEMBL30312239 | 0.80 | BACE1 (0.57) | BACE1 | |
| SCHEMBL2735762 | 0.79 | APC (0.52) | APCQRFPRKEAP1PTPN1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133111-A1 | CGRP RECEPTOR AGONISTS IN ISCHEMIC HEART DISEASE | EPOQE PHARMA APS (DK) | 2025-06-26 | — | — | WO | claimed |
| EP-2964658-B1 | POSITRON-EMITTING SUBSTITUTED ORGANOFLUOROBORATES AS IMAGING AGENTS | UNIV BRITISH COLUMBIA (CA) | 2024-08-07 | — | — | EP | claimed |
| CN-114099775-A | HAp-SF artificial periosteum loading SDF-1 alpha/CGRP and preparation method thereof | 华南理工大学 | 2022-03-01 | — | — | CN | claimed |
| EP-4748439-A2 | A PEPTOID-PEPTIDE HYBRID, NMEG-ALPHA-CGRP, AND ITS USE IN CARDIOVASCULAR DISEASES | University of South Carolina (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3609434-B1 | MEDICAL DEVICES COATED WITH POLYDOPAMINE AND ANTIBODIES | ORBUSNEICH MEDICAL PTE LTD (SG) | 2026-05-20 | — | — | EP | disclosed |
| EP-4705339-A1 | COMPOSITION, METHODS AND USES | 4E Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-121426953-A | Preparation method of CGRP detection kit and application of CGRP detection kit in migraine diagnosis | 江苏美克医学技术有限公司 | 2026-01-30 | — | — | CN | disclosed |
| EP-3970725-B1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2025-08-20 | — | — | EP | disclosed |
| WO-2025133111-A1 | CGRP RECEPTOR AGONISTS IN ISCHEMIC HEART DISEASE | EPOQE PHARMA APS (DK) | 2025-06-26 | — | — | WO | disclosed |
| US-20250186595-A1 | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN | TRIDEM BIOSCIENCE GMBH & CO KG (AT) | 2025-06-12 | — | — | US | disclosed |
| US-20250186580-A1 | A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN | TRIDEM BIOSCIENCE GMBH & CO KG (AT) | 2025-06-12 | — | — | US | disclosed |
| CN-114245798-A | CGRP antagonist compounds | 赫普泰雅治疗有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-108025044-B | Immunogenic procalcitonin precursor peptides | 古斯塔夫鲁西研究院 | 2022-03-25 | — | — | CN | disclosed |
| EP-3970725-A1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | Massachusetts Eye & Ear Infirmary (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3165236-B1 | METHODS FOR TREATING VISCERAL PAIN BY ADMINISTERING ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE | TEVA PHARMACEUTICALS INT GMBH (CH) | 2022-03-16 | — | — | EP | disclosed |
| CN-114099775-A | HAp-SF artificial periosteum loading SDF-1 alpha/CGRP and preparation method thereof | 华南理工大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-114099775-A | HAp-SF artificial periosteum loading SDF-1 alpha/CGRP and preparation method thereof | 华南理工大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-114099775-A | HAp-SF artificial periosteum loading SDF-1 alpha/CGRP and preparation method thereof | 华南理工大学 | 2022-03-01 | — | — | CN | disclosed |
| EP-3016684-B1 | REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES | H LUNDBECK AS (DK) | 2022-02-23 | — | — | EP | disclosed |
| US-11254932-B2 | Conditionally active biological proteins | BIOATLA, INC. (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186595-A1 | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN | CD4, CD74, CD47 | APC 2038/4885BACE1 769/4885QRFPR 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.